- Home
- OCTO vs RDHL Comparison
OCTO vs RDHL Comparison
Compare OCTO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCTO
- RDHL
- Stock Information
- Founded
- OCTO 1966
- RDHL 2009
- Country
- OCTO United States
- RDHL Israel
- Employees
- OCTO N/A
- RDHL N/A
- Industry
- OCTO
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- OCTO
- RDHL Health Care
- Exchange
- OCTO Nasdaq
- RDHL Nasdaq
- Market Cap
- OCTO 4.2M
- RDHL 3.8M
- IPO Year
- OCTO N/A
- RDHL N/A
- Fundamental
- Price
- OCTO $1.30
- RDHL $1.79
- Analyst Decision
- OCTO
- RDHL
- Analyst Count
- OCTO 0
- RDHL 0
- Target Price
- OCTO N/A
- RDHL N/A
- AVG Volume (30 Days)
- OCTO 46.3K
- RDHL 219.3K
- Earning Date
- OCTO 05-16-2025
- RDHL 04-10-2025
- Dividend Yield
- OCTO N/A
- RDHL N/A
- EPS Growth
- OCTO N/A
- RDHL N/A
- EPS
- OCTO N/A
- RDHL N/A
- Revenue
- OCTO $41,576,562.00
- RDHL $8,042,999.00
- Revenue This Year
- OCTO N/A
- RDHL $381.91
- Revenue Next Year
- OCTO N/A
- RDHL N/A
- P/E Ratio
- OCTO N/A
- RDHL N/A
- Revenue Growth
- OCTO N/A
- RDHL 23.17
- 52 Week Low
- OCTO $0.98
- RDHL $1.71
- 52 Week High
- OCTO $4.86
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- OCTO 50.35
- RDHL 35.19
- Support Level
- OCTO $1.21
- RDHL $1.76
- Resistance Level
- OCTO $1.39
- RDHL $1.93
- Average True Range (ATR)
- OCTO 0.12
- RDHL 0.11
- MACD
- OCTO -0.01
- RDHL 0.02
- Stochastic Oscillator
- OCTO 28.67
- RDHL 23.53
About OCTO Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.